Semax Research Guide: Nootropic Peptide Science

What is Semax?

Semax is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH) sequence. It was developed in Soviet-era Russia at the Institute of Molecular Genetics of the Russian Academy of Sciences, with research origins dating to the 1980s. It represents one of the most significant outputs of the Russian nootropic peptide research programme — a research tradition that produced several compounds with well-documented neurological effects in preclinical models.

Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)

Molecular Weight: 813.94 Da

CAS Number: 80714-61-0

Molecular Formula: C₃₇H₅₁N₉O₁₀S

The parent sequence from which Semax is derived is the ACTH(4-7) fragment: Met-Glu-His-Phe. This four-amino acid core is the minimal sequence of ACTH required to produce neurological activity without the adrenal steroidogenic effects of the full ACTH peptide. The Pro-Gly-Pro C-terminal extension added in Semax was a deliberate structural modification designed to dramatically improve metabolic stability — a recurring challenge with short neuropeptides in biological systems.

---

Historical Development

The development of Semax emerged from a broader Soviet and subsequently Russian programme investigating the neurological activity of ACTH fragments. Full ACTH (a 39-amino acid peptide) was known to have effects on learning, memory, and attention independent of its adrenal actions — effects attributed to the 4-7 fragment of the ACTH sequence.

The challenge faced by researchers was that ACTH(4-7) alone, while neurologically active, was rapidly degraded by endopeptidases in biological fluids, severely limiting its usefulness as a research tool. The Pro-Gly-Pro extension introduced in Semax addressed this limitation directly — proline residues at key positions create steric resistance to proteolytic cleavage, while the C-terminal prolyl amide further stabilises the molecule against carboxypeptidases.

The result was a compound with the neurological activity profile of ACTH(4-7) combined with a dramatically improved half-life in biological systems. Semax was subsequently developed in Russia as a registered pharmaceutical (under the brand name Semax nasal drops) — one of the few synthetic peptides to achieve pharmaceutical approval based primarily on research conducted within the Soviet/Russian research system.

---

ACTH(4-7) and the Pro-Gly-Pro Extension

Understanding the two components of Semax's structure helps contextualise its research profile:

The ACTH(4-7) Core

The Met-Glu-His-Phe core sequence interacts with melanocortin receptors (particularly MC4R, which is expressed throughout the CNS) and appears to modulate monoaminergic neurotransmission — specifically dopaminergic and serotonergic pathways — through mechanisms not yet fully characterised.

The fragment also appears to interact directly with BDNF pathways: research suggests that ACTH(4-7) and its analogues can upregulate brain-derived neurotrophic factor (BDNF) expression in neural tissue, which provides one mechanistic hypothesis for the cognitive and neuroprotective effects observed in research models.

The Pro-Gly-Pro Extension

The C-terminal Pro-Gly-Pro addition serves multiple functions:

1. Metabolic stability: Proline residues create steric hindrance that resists proteolytic cleavage, significantly extending the biological half-life of the peptide

2. Conformational tuning: The C-terminal extension influences the three-dimensional conformation of the active core, potentially optimising receptor binding geometry

3. Independent CNS activity: Interestingly, Pro-Gly-Pro itself has been shown to have independent neurological activity as a fragment of collagen metabolism — it is an endogenous collagen breakdown product with reported effects on dopaminergic and GABAergic pathways. This means Semax may act through the combined and potentially synergistic activity of both its structural components

---

Key Research Areas

BDNF Upregulation Research

One of the most reproduced findings in Semax preclinical research is the upregulation of brain-derived neurotrophic factor (BDNF) and its receptor, TrkB. BDNF is a critical growth factor for the survival, maintenance, and differentiation of neurons, and is implicated in synaptic plasticity — the cellular mechanism underlying learning and memory.

Studies in rodent models have demonstrated increased BDNF mRNA expression in the hippocampus, cerebral cortex, and frontal lobe following Semax administration. The magnitude and duration of BDNF upregulation appears to be dose-dependent, with effects persisting beyond the period of active compound presence — consistent with a gene expression-level rather than purely receptor-binding mechanism.

For in-vitro research, Semax can be applied to primary neuronal cultures or neuroblastoma cell lines to study BDNF pathway activation, TrkB receptor signalling, and downstream CREB phosphorylation in a controlled cell model context.

Neuroprotective Effects in Ischaemia Models

Semax has been studied extensively in rodent cerebral ischaemia models — both permanent and transient middle cerebral artery occlusion (MCAO) paradigms. Key findings include:

• •Reduced infarct volume in multiple rodent MCAO studies
• •Attenuation of neuroinflammation: Reduced expression of pro-inflammatory cytokines (TNF-α, IL-1β) in ischaemic brain tissue
• •Oxidative stress reduction: Decreased lipid peroxidation markers and enhanced antioxidant enzyme activity in neural tissue
• •Preservation of neurological function scores in behavioural assessments post-ischaemia

These findings establish Semax as a useful tool for studying the molecular mechanisms of ischaemic neuroprotection. In-vitro ischaemia models — such as oxygen-glucose deprivation (OGD) in neuronal cell cultures — can employ Semax to investigate which specific protective pathways are engaged under simulated ischaemic conditions.

Cognitive Function and Memory Models

Rodent models of cognitive function — Morris water maze, novel object recognition, contextual fear conditioning — have been employed extensively in Semax research. Consistent findings include improvements in spatial learning, memory consolidation, and attentional parameters in multiple rodent strains and experimental conditions.

Critically, these cognitive effects are observed not only in models of cognitive impairment (age-related decline, ischaemia-induced deficits, cholinergic lesion models) but also in otherwise healthy animals — an important distinction that has attracted significant interest in Semax as a tool for studying the basic neurochemistry of cognitive enhancement.

The mechanism underlying cognitive effects is thought to involve:

• •BDNF/TrkB-mediated enhancement of synaptic plasticity
• •Monoaminergic pathway modulation (dopamine and serotonin turnover changes)
• •Potential direct effects on NMDA and AMPA receptor function in hippocampal synapses

Dopaminergic and Serotonergic Modulation

Semax research has consistently identified changes in monoamine neurotransmitter dynamics following administration. Neurochemical studies in rodents have reported:

• •Dopamine system: Increased dopamine and DOPAC levels in frontal cortex and striatum; altered dopamine receptor expression in relevant brain regions
• •Serotonin system: Increased serotonin and 5-HIAA levels in specific brain regions; potential upregulation of serotonin transporter expression
• •Norepinephrine: Some studies report changes in norepinephrine turnover, though findings are less consistent across the literature

For cell culture research, the dopaminergic effects of Semax can be studied in dopaminergic neuron preparations (PC12 cells, primary ventral mesencephalic cultures) to characterise the molecular targets through which Semax exerts its monoaminergic effects.

---

Comparison with Related Compounds

N-Acetyl Semax

N-Acetyl Semax is a modified form of Semax with an N-terminal acetyl group. This modification confers additional metabolic stability by protecting the alpha-amino group from aminopeptidase activity. N-Acetyl Semax is reported to have a longer effective duration in biological systems and may exhibit a somewhat different potency profile, though the fundamental pharmacological actions are consistent with unmodified Semax.

Selank

Selank (TKPRPGP) is another peptide developed by the same Russian research group, derived from the immunomodulatory peptide tuftsin. Where Semax research focuses predominantly on cognitive enhancement and neuroprotection, Selank research emphasises anxiolytic and anti-stress effects through modulation of the GABAergic system and enkephalin metabolism. The two compounds are sometimes studied together to differentiate cognitive enhancement effects from anxiolytic effects — useful for researchers interested in disentangling these commonly co-occurring variables.

---

How Nootropic Peptides Differ from Small-Molecule Cognitive Drugs

Nootropic peptides like Semax differ fundamentally from small-molecule cognitive drugs (amphetamines, racetams, modafinil) in several important ways that have research implications:

This profile makes peptides like Semax particularly interesting for research into sustainable cognitive enhancement and neuroprotection mechanisms, as distinct from the stimulant pharmacology of conventional cognitive drugs.

---

Research Administration Routes and Reconstitution Protocols

Semax has been studied via multiple administration routes in preclinical research:

• •Intranasal: The most commonly used route in rodent research, exploiting the olfactory route for direct CNS delivery bypassing the blood-brain barrier
• •Subcutaneous: Standard parenteral route for systemic peptide delivery
• •Intraperitoneal: Commonly used in rodent studies for systemic delivery

For in-vitro research applications, Semax is added directly to cell culture media at defined concentrations, circumventing route-of-delivery considerations.

Reconstitution Protocol

Semax 10mg is supplied as lyophilised powder and should be reconstituted as follows:

1. Allow vial to equilibrate to room temperature before opening

2. Wipe rubber stopper with alcohol swab; allow to dry

3. Using a sterile syringe, draw the desired volume of Bacteriostatic Water 10mL

4. Inject BAC water slowly down the inner vial wall — do not direct the stream at the lyophilised cake

5. Gently swirl until fully dissolved. Semax dissolves readily and produces a clear, colourless solution

6. Draw working aliquots using 31G insulin needles for precise, low-dead-volume transfer

7. Label vial with compound, concentration, and date

Concentration Reference for Semax 10mg

---

Storage Considerations

Lyophilised Semax should be stored at −20°C for long-term preservation (up to 24 months). Reconstituted solutions should be maintained at 2–8°C and used within 28 days. Protect all forms from light, as photooxidation of the methionine residue (position 1 of the sequence) can reduce biological activity.

For multi-experiment programmes, it is good practice to prepare stock aliquots from the reconstituted vial shortly after reconstitution, freeze them at −20°C, and thaw individual aliquots as needed — this minimises the number of freeze-thaw cycles experienced by the main stock.

---

Conclusion

Semax occupies a distinctive position in the research peptide landscape as one of the few neuropeptides with both deep preclinical data and pharmaceutical-level validation from the Russian research system. Its ACTH-derived sequence, enhanced metabolic stability through the Pro-Gly-Pro extension, and multi-pathway CNS activity profile — spanning BDNF upregulation, monoaminergic modulation, and neuroprotection — make it a uniquely versatile tool for neurological research.

Semax 10mg is available for research purposes from Peptide Warehouse Australia, independently verified for purity by HPLC with mass spectrometry identity confirmation.

Disclaimer: All information is for educational and research purposes only. Products are for in-vitro laboratory research use only. Not for human consumption, therapeutic use, or veterinary use. Comply with all applicable Australian laws.